http://orcid.org/0000-0002-5555-7362
References
- Arnold DM, Nazi I, Kelton JG. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. Expert Opin Investig Drugs. 2009;18(6):805–819. doi:10.1517/13543780902905848.
- Josefsson EC, Burnett DL, Lebois M, Debrincat MA, White MJ, Henley KJ, Lane RM, Moujalled D, Preston SP, O’Reilly LA, Pellegrini M, Metcalf D, Strasser A, Kile BT. Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways. Nat Commun. 2014;5:3455. doi:10.1038/ncomms4455.
- Avanzi MP, Izak M, Oluwadara OE, Mitchell WB, Mandal M. Actin inhibition increases megakaryocyte proplatelet formation through an apoptosis-dependent mechanism. PLoS One. 2015;10(4):e0125057. doi:10.1371/journal.pone.0125057.
- Yang L, Wang L, Zhao CH, Zhu X-J, Hou Y, Jun P, Hou M. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010;116(20):4307–4316. doi:10.1182/blood-2010-02-267435.
- Houwerzijl EJ, Blom NR, Van Der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2):500–506. doi:10.1182/blood-2003-01-0275.
- Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984.
- De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100(4):1310–1317. doi:10.1182/blood-2002-03-0686.